Rigel Pharmaceuticals (RIGL) is a stock many investors are watching right now. RIGL is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. Value investors also love the P ...

Rigel Pharmaceuticals has demonstrated strong financial performance in recent quarters, with a notable revenue beat in Q3 2024. The company reported revenue of $55.3 million, surpassing the ...

One stock to keep an eye on is Rigel Pharmaceuticals (RIGL). RIGL is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. Value investors also frequently use the P/S ratio.

Title: Efficacy and Safety of Pralsetinib in Patients with Advanced RET-fusion-positive NSCLC: Final Data from the Phase 1/2 ARROW Study Presenter: Eunice S. Wang, M.D. A post-hoc analysis of ...

Presenter: Eunice S. Wang, M.D. A post-hoc analysis of the pivotal cohort from the Phase 1/2 study evaluated outcomes in patients with R/R mIDH1 AML who received olutasidenib after either 1-2 or ...

Short interest in Rigel Pharmaceuticals Inc (NASDAQ:RIGL) increased during the last reporting period, rising from 1.85M to 2.08M. This put 11.96% of the company's publicly available shares short.

From Kat Slade to Dr Danielle Harel and Joy Rigel, meet the experts starring in Channel 4's controversial new series 'Virgin Island'. Virgin Island is a new groundbreaking series on Channel 4 ...

Almost a year to the day after Roche pulled out a partnership on its underperforming cancer therapy Gavreto, Blueprint Medicines has sold US commercial rights to the drug to Rigel Pharma in a deal ...

Joy Rigel is an emotional intimacy coach with over two decades of experience in the field. According to her website, Joy supports those "who feel disconnected", whether it be from their bodies ...